Study Demonstrates 16.6 % at day 7 to 29 % on terminal day 28 Weight Loss and Superior Efficacy Compared to peptide-based approved or clinical stage oral Obesity Drugs in the DIO Model LEHI, Utah, Dec ...
FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT), an early-stage biotechnology company, today announced early data from two non-Good Laboratory ...
13-week follow-up represents the longest data to-date demonstrating durable efficacy of RJVA-001 on weight and blood sugar in the diet-induced obesity (DIO) mouse model Company plans to use durable ...
Honda has introduced the latest version of its popular sporty scooter – the 2025 Dio 125. Now updated to meet the stricter OBD2B emission standards, the new Dio 125 packs in fresh styling and feature ...
The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model ALN1003 also demonstrated reductions in liver weight and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results